

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jul 2026

### To evaluate the effect of garlic tablet on metabolic syndrome in PCOS patients : A Randomized Double-blind Placebo-controlled Trial

#### Protocol summary

##### Study aim

The effect of garlic tablets on metabolic syndrome in patients with poly cystic ovary syndrome(PCOS)

##### Design

A randomized, double-blind, placebo-controlled clinical trial with control group in parallel with a calculated sample size of 36 patients in each group totaling 72 patients.

##### Settings and conduct

Samples were selected from women referring to the infertility clinic of Arash Women General Hospital who met the inclusion criteria and were randomly assigned to one of two intervention or control groups. The intervention duration is 8 weeks and these patients will be evaluated at the beginning of the study and at the end of the eighth week.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: age 15 to 49 years / unwilling to participate in the study / not pregnant / not having diabetes Mellitus / not having other chronic illnesses / not taking blood lipids and anticoagulants / minimal reading and writing literacy / Consume a maximum of one garlic per day  
Exclusion criteria: unwillingness to continue participation / occurrence of any side effects caused by medication and intervention.

##### Intervention groups

Intervention group: Garlic tablets 500 mg twice daily for 8 weeks along with other medications such as Metformin  
Control group: Garlic placebo in the same dose and form for 8 weeks.

##### Main outcome variables

Plasma Level of FBS/ Triglyceride/ HDL/Cholesterol total  
Level of systolic and diastolic blood pressure  
Waist-to-hip ratio and weight (WHR)

#### General information

##### Reason for update

Completion of the sampling process and statistical

analysis led us to update the recorded information of different sections of this trial in IRCT. As we have believed that this study might hold enormous potential for improving promising therapeutic agents to benefit patients who are suffering from various manifestations of endometriosis, especially endometrioma. Unfortunately, while updating the information related to the actual recruitment start/end dates, we noticed an inadvertent error in recording the expected recruitment start and end dates of the sampling, and a need has been felt on the imperative for transparency, accountability in order to fix that error and explain its causes to re-establish researchers' trust in this clinical trial's accuracy and reliability. All available evidence, including the date of approval of this clinical trial in the ethics committee of Tarbiat Modares University (IR.MODARES.REC.1398.142) and the date of entry of the researcher to the master's degree (1397-98 academic year) indicate an inadvertent error in the registration of this study and make the possibility of conducting this study in that time (before registration) unfeasible. We take full responsibility for the situation and all of patients' consents and questionnaire forms with detailed for the current study are available upon any requests. In addition, the simultaneous recruiting of patients and the coronavirus pandemic and its lockdown resulted in study participants' inaccessibility and trial personnel for in-person scheduled study visits and/or follow-up led to prolong sampling process and its postponement.

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20150905023897N4**

Registration date: **2019-11-09, 1398/08/18**

Registration timing: **prospective**

Last update: **2023-03-04, 1401/12/13**

Update count: **1**

##### Registration date

2019-11-09, 1398/08/18

##### Registrant information

**Name**

Dr. Shahideh Jahanian Sadatmahalleh

**Name of organization / entity**

Tarbiat Modares University

**Country**

Iran (Islamic Republic of)

**Phone**

+98 21 8288 4826

**Email address**

shahideh.jahanian@modares.ac.ir

**Recruitment status**

**Recruitment complete**

**Funding source****Expected recruitment start date**

2019-10-23, 1398/08/01

**Expected recruitment end date**

2020-05-21, 1399/03/01

**Actual recruitment start date**

2020-01-07, 1398/10/17

**Actual recruitment end date**

2021-01-04, 1399/10/15

**Trial completion date**

2021-04-12, 1400/01/23

**Scientific title**

To evaluate the effect of garlic tablet on metabolic syndrome in PCOS patients : A Randomized Double-blind Placebo-controlled Trial

**Public title**

To evaluate the effect of garlic tablet on metabolic syndrome in PCOS patients : A Randomized Double-blind Placebo-controlled Trial

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

People are willing to participate in the study fertility age between 15-49 years Iranian women no pregnancy have at least literacy for read and write no Mellitus Diabets according to primary FBS no chronic and coagulation disorders lack of consumption Anti lipids and Anti hypertensive and anti coagulative drugs no consuming garlic in a daily diet more than one cubit

**Exclusion criteria:**

People with drug side effects. Individuals unwilling to continue to participate in the study failure to comply with treatment protocol

**Age**

From **15 years** old to **49 years** old

**Gender**

Female

**Phase**

2

**Groups that have been masked**

- Participant
- Investigator

**Sample size**

Target sample size: **90**

Actual sample size reached: **97**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients are randomly divided into two groups according to the blocking method and double blind

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The researcher and patient will be unaware of the treatment and grouping of the study. For this purpose, Garlic tablets and placebo are coded by a research center. The lead researcher treats patients in a double-blind manner based on the drug package code. The code for the drug package is recorded on the personal information form, and the researcher who completes the information form will not be informed of the type of treatment.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tarbiat Modares university

**Street address**

Jalal E Al Ahmad

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۱۱۷۱۳۱۱۶

**Approval date**

2019-11-02, 1398/08/11

**Ethics committee reference number**

IR.MODARES.REC.1398.142

**Health conditions studied****1****Description of health condition studied**

Metabolic syndrome in PCOS patients

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

level of Triglyceride

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

blood biochemistry test

**2**

**Description**

level of cholesterol

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

blood biochemistry test

**3**

**Description**

blood level of HDL

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

blood biochemistry test

**4**

**Description**

blood level of FBS

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

blood biochemistry test

**5**

**Description**

level of systolic and diastolic blood pressure

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

Use of mercury barometer

**6**

**Description**

Waist to hip ratio

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

Use of meter

**Secondary outcomes**

**1**

**Description**

Level of CRP

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

Blood biochemistry test

**2**

**Description**

menstrual dysfunction such as: Oligomenorrhea and amenorrhea

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

patient statements

**3**

**Description**

clinical hyperandrogenemia

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

Blood biochemistry test and clinical symptom

**4**

**Description**

Ultrasound view of the ovaries

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

Use of ultrasound

**5**

**Description**

sexual function

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

FSFI questionnaire

**6**

**Description**

Quality Of life

**Timepoint**

First of study and 8 weeks after intervention

**Method of measurement**

MPCOSQ questionnaire

**Intervention groups**

**1**

**Description**

Intervention group: Treatment by garlic tab 500 mg

**Category**

Treatment - Drugs

**2**

**Description**

Control group: treatment by placebo of garlic tab

**Category**

Placebo

## Recruitment centers

1

### Recruitment center

**Name of recruitment center**

Arash hospital

**Full name of responsible person**

Shahideh Jahanian Sadatmahalleh

**Street address**

Shahid baghdarnia Ave

**City**

Tehran

**Province**

Tehran

**Postal code**

1653915981

**Phone**

+98 21 7788 3283

**Fax**

+98 21 7788 3196

**Email**

hosp\_arash@tums.ac.ir

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**

Tarbiat modares University

**Full name of responsible person**

Shahideh Jahanian Sadatmahalleh

**Street address**

Jalal E AL Ahmad

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۱۱۷۱۳۱۱۶

**Phone**

+98 21 8800 6544

**Fax**

+98 21 8800 6544

**Email**

pres@modares.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tarbiat modares University

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

## Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Tarbiat modares University

**Full name of responsible person**

Shahideh Jahanian Sadatmahalleh

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Midwifery

**Street address**

Jalal E Al Ahmad

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۱۱۷۱۳۱۱۶

**Phone**

+98 21 2230 6480

**Fax**

+98 21 8288 4826

**Email**

Shahideh.jahanian@modares.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Tarbiat Modares University

**Full name of responsible person**

Shahideh Jahanian Sadatmahalleh

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Midwifery

**Street address**

Jalal E Al Ahmad

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۱۱۷۱۳۱۱۶

**Phone**

+98 21 2230 6480

**Fax**

+98 21 8288 4826

**Email**

shahideh.jahanian@modares.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Tarbiat Modares University

**Full name of responsible person**

Shahideh Jahanian Sadatmahalleh

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Midwifery

**Street address**

Jalal E Al Ahmad

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۱۱۷۱۳۱۱۶

**Phone**

+98 21 2230 6480

**Fax**

+98 21 8288 4826

**Email**

shahideh.jahanian@modares.ac.ir

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

No - There is not a plan to make this available

### Statistical Analysis Plan

No - There is not a plan to make this available

### Informed Consent Form

No - There is not a plan to make this available

### Clinical Study Report

No - There is not a plan to make this available

### Analytic Code

No - There is not a plan to make this available

### Data Dictionary

No - There is not a plan to make this available

### Title and more details about the data/document

Information on the main outcome of the study

### When the data will become available and for how long

1400

### To whom data/document is available

Academic researchers

### Under which criteria data/document could be used

Use for further research in the future

### From where data/document is obtainable

Email Addressing Responsible for Study

### What processes are involved for a request to access data/document

Submit a request to study and follow up

### Comments